Senate VA Committee Passes Legislation on Hyperbaric Oxygen Therapy
Back in October 2019, at Senator Cramer’s invitation, VA Secretary Robert Wilkie and the Senator toured Healing with Hyperbarics of North Dakota, a Fargo-based HBOT clinic. Cramer states, “The primary point of the federal government is the defense of our nation. Part...Oxygen Under Pressure Resolving TBI’s & Suicide – Hailed as Most Important Scientific Breakthrough for 2019
Research Triangle Park, NC (January 21, 2020) – Congressman Andy Biggs (AZ-05) and Senator Kevin Cramer (R-ND) recently introduced the TBI and PTSD Treatment Act [House Bill 4370; Senate Bill 2504], in late 2019 to direct the Veterans Administration (VA) to...Study Reveals Oxygen-Rich Air Can Reverse Severe Brain Damage
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.